NCT03210532View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia

PHASE3CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

October 7, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
HypertensionDyslipidemia
Interventions
DRUG

Telmisartan + Amlodipine + Rosuvastatin

Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo

DRUG

Telmisartan + Amlodipine

Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo

DRUG

Telmisartan + Rosuvastatin

Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo

Trial Locations (1)

Unknown

Sevrance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Daewon Pharmaceutical Co., Ltd.

INDUSTRY